Marlise Rachael Luskin, MD, MSCE

In this final segment, Dr Luskin discusses treatment sequencing considerations in blastic plasmacytoid dendritic cell neoplasm (BPDCN), with a focus on integrating targeted therapy and allogeneic stem cell transplantation.

This segment addresses the clinical implications of disease burden in blastic plasmacytoid dendritic cell neoplasm (BPDCN), a condition that frequently presents with extensive skin involvement or other high-burden manifestations.

This segment focuses on safety considerations associated with tagraxofusp in the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN), with an emphasis on early toxicity recognition in community oncology settings

In this segment, Dr Luskin examines how patient-related factors influence treatment decisions in blastic plasmacytoid dendritic cell neoplasm (BPDCN), a disease that predominantly affects older adults

Discover the latest advancements in BPDCN treatment, including targeted therapies and promising chemotherapy regimens for better patient outcomes.

Explore the complexities of blastic plasmacytoid dendritic cell neoplasm, its challenges in diagnosis, and advancements in targeted therapies for better outcomes.